Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.37 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | GLS | O94925 | 1/20 | 0.33 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.32 |
| ▸ | PRKCI | P41743 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31468983 | 0.85 | HTR2C (0.38) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL8164937 | 0.82 | HTR2C (0.38) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL8169426 | 0.82 | RIPK1 (0.46) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL8169606 | 0.82 | SLC6A4 (0.42) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL18186254 | 0.82 | HTR2C (0.38) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL545286 | 0.82 | CACNA1G (0.47) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL5912956 | 0.82 | HTR2C (0.36) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL13631348 | 0.82 | SLC6A4 (0.38) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL1399430 | 0.81 | HTR2C (0.43) | HTR2CSLC6A4CACNA1GCACNA1BCACNA1C | |
| SCHEMBL7246130 | 0.81 | MEN1 (0.42) | HTR2CSLC6A4MTNR1AMTNR1BAAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871753-B2 | Macrocyclic compounds and their use as kinase inhibitors | INCYTE CORPORATION (US) | 2014-10-28 | — | — | US | disclosed |
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-11-19 | — | — | US | disclosed |
| WO-2009132202-A2 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286778-A1 | MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | JAK2, JAK1, ALK | HTR2C 4197/4885SLC6A4 4530/4885CACNA1G 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.